Ze zijn wat verder als Intellia wat betreft medicijn ontwikkeling. Ze hebben ook een big pharma partner:
On November 6, CRISPR Therapeutics AG (NASDAQ:CRSP) reported a Q3 GAAP EPS of -$1.41, beating market estimates by $0.57. As of September 30, 2023, cash, cash equivalents, and marketable securities amounted to $1,739.8 million, reflecting a decrease of $128.6 million from the $1,868.4 million reported on December 31, 2022. The decline was primarily attributed to operating expenses but partially offset by payments received from Vertex, associated with a non-exclusive license agreement, along with interest income.
Ik denk dat gene editing gaat doorbreken komende jaren en de toepassingen zijn talloos. Ik ben misschien wat overenthousiast.